Alligator Bioscience soars on positive mitazalimab trial
Shares of Sweden’s immune-oncology firm Alligator Bioscience (STO: ATORX) were up almost 160% at 0.11 kronor by early afternoon today, after the company reported updated results from the Phase II OPTIMIZE-1 study evaluating mitazalimab in combination with standard chemotherapy (mFOLFIRINOX) as a first-line treatment for metastatic pancreatic cancer.
The company noted that the 24-month analysis of the 900µg/kg dose reconfirms and extends the significant survival benefit and reinforces the potential of mitazalimab as a breakthrough immunotherapy candidate in this challenging disease.
The data demonstrated a 24-month survival rate of 29.4% in patients treated with mitazalimab in combination with mFOLFIRINOX. These numbers compare well to estimates of 24-month survival rates of 8% for FOLFIRINOX alone, and 20% for NALIRIFOX alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze